Time course of 8-methoxypsoralen-induced skin photosensitization in PUVA-bath photochemotherapy. 1997

T Reuther, and C Gruss, and S Behrens, and G von Kobyletzki, and N Neumann, and P Lehmann, and P Altmeyer, and M Kerscher
Ruhr-University, Bochum, Germany.

In recent years PUVA-bath photochemotherapy has been shown to be an effective treatment modality for several dermatoses. A limitation of PUVA-bath photochemotherapy has been the lack of guidelines for optimal performance, including the time course of photosensitization of the skin exposed to the 8-methoxypsoralen (8-MOP) bath water solution. In the present study 12 healthy volunteers were exposed to a 20 min bath in 150 l of an 8-MOP water solution (0.5 mg/l, 37 degrees C). Immediately, as well as 1, 2, 3 and 5 h after the 8-MOP bath, irradiation was performed with increasing doses of UVA (0.5, 1, 2, 3, 5 J/cm2) on 2 cm2 test areas. The minimal phototoxic dose (MPD) was determined 72 h after the UVA exposure. In all volunteers, photosensitization was highest immediately after the bath, with a MPD significantly below 5 J/cm2 (0.5-2 J/cm2). One hour after the bath, erythema could be induced by 2 to 5 J/cm2 UVA. Two hours after the bath, erythema could be induced using irradiation of 5 J/cm2 only in two volunteers. Three and five hours after the 8-MOP bath, no erythema could be induced in any volunteer by UVA doses up to 5 J/cm2. Our results indicate that optimal bath-PUVA requires UVA irradiation immediately after the 8-MOP bath. Further, these results imply that no restrictions on further sun exposure are mandatory 3 h after the 8-MOP bath, thus allowing the patient to pursue normal life activities.

UI MeSH Term Description Entries
D008297 Male Males
D008730 Methoxsalen A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA ADDUCTS in the presence of ultraviolet A irradiation. 8-Methoxypsoralen,Ammoidin,Xanthotoxin,8-MOP,Deltasoralen,Dermox,Geroxalen,Meladinina,Meladinine,Meloxine,Methoxa-Dome,Méladinine,Oxsoralen,Oxsoralen-Ultra,Puvalen,Ultramop,8 MOP,8 Methoxypsoralen,8MOP,Methoxa Dome,Oxsoralen Ultra
D011701 PUVA Therapy Photochemotherapy using PSORALENS as the photosensitizing agent and ultraviolet light type A (UVA). Psoralen Ultraviolet A Therapy,Therapy, PUVA,PUVA Therapies,Therapies, PUVA
D004890 Erythema Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes. Erythemas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012867 Skin The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D017319 Photosensitizing Agents Drugs that are pharmacologically inactive but when exposed to ultraviolet radiation or sunlight are converted to their active metabolite to produce a beneficial reaction affecting the diseased tissue. These compounds can be administered topically or systemically and have been used therapeutically to treat psoriasis and various types of neoplasms. Photosensitizer,Photosensitizers,Photosensitizing Agent,Photosensitizing Effect,Photosensitizing Effects,Agent, Photosensitizing,Agents, Photosensitizing,Effect, Photosensitizing,Effects, Photosensitizing

Related Publications

T Reuther, and C Gruss, and S Behrens, and G von Kobyletzki, and N Neumann, and P Lehmann, and P Altmeyer, and M Kerscher
March 1997, The British journal of dermatology,
T Reuther, and C Gruss, and S Behrens, and G von Kobyletzki, and N Neumann, and P Lehmann, and P Altmeyer, and M Kerscher
January 1998, Photodermatology, photoimmunology & photomedicine,
T Reuther, and C Gruss, and S Behrens, and G von Kobyletzki, and N Neumann, and P Lehmann, and P Altmeyer, and M Kerscher
May 1999, The British journal of dermatology,
T Reuther, and C Gruss, and S Behrens, and G von Kobyletzki, and N Neumann, and P Lehmann, and P Altmeyer, and M Kerscher
August 2000, Photodermatology, photoimmunology & photomedicine,
T Reuther, and C Gruss, and S Behrens, and G von Kobyletzki, and N Neumann, and P Lehmann, and P Altmeyer, and M Kerscher
July 1990, Clinical and experimental dermatology,
T Reuther, and C Gruss, and S Behrens, and G von Kobyletzki, and N Neumann, and P Lehmann, and P Altmeyer, and M Kerscher
August 2000, Photodermatology, photoimmunology & photomedicine,
T Reuther, and C Gruss, and S Behrens, and G von Kobyletzki, and N Neumann, and P Lehmann, and P Altmeyer, and M Kerscher
January 1984, Clinical and experimental dermatology,
T Reuther, and C Gruss, and S Behrens, and G von Kobyletzki, and N Neumann, and P Lehmann, and P Altmeyer, and M Kerscher
October 2000, Photodermatology, photoimmunology & photomedicine,
T Reuther, and C Gruss, and S Behrens, and G von Kobyletzki, and N Neumann, and P Lehmann, and P Altmeyer, and M Kerscher
March 2002, Clinical pharmacology and therapeutics,
T Reuther, and C Gruss, and S Behrens, and G von Kobyletzki, and N Neumann, and P Lehmann, and P Altmeyer, and M Kerscher
January 2005, Acta dermato-venereologica,
Copied contents to your clipboard!